Interim analysis of first-in-human phase 1 study to assess safety and efficacy of YBL-006, an anti-PD-1 antibody in advanced solid tumor with exploratory biomarker analysis of tumor mutational burden and artificial intelligence (AI)-powered spatial analysis of tumor-infiltrating lymphocytes.

被引：0
|
作者：
Park, John J.
Lee, Keun Wook
Oh, Do-Youn
Sabanathan, Dhanusha
Kim, Se Hyun
Kim, Tae Min
Kim, Myungsuk
Yoon, Jaebong
Lee, Hyunmi
Kim, Boram
Ko, Yunjung
Jeon, Eunyoung
Cheon, Seonghye
Shim, Eunyoung
Park, Bum-Chan
Lee, Han Seung
Park, Seongyeol
Paeng, Kyunghyun
Ock, Chan-Young
机构：
[1] Macquarie Univ, Dept Clin Med, Sydney, NSW, Australia
[2] Seoul Natl Univ, Coll Med, Bundang Hosp, Seongnam, South Korea
[3] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Canc Res Inst, Seoul, South Korea
[4] Y Biol Inc, Daejeon, South Korea
[5] Genome Insight Inc, Daejeon, South Korea
[6] Lunit Inc, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e14552
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14552
引用
收藏
页数：3
相关论文
共 12 条
  • [1] Artificial intelligence (AI)-powered spatial analysis of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker for anti-PD-1 in advanced biliary tract cancer (BTC)
    Bang, Y.
    Lee, C-K.
    Bang, K.
    Kim, H-D.
    Kim, K-P.
    Jeong, J. H.
    Ryoo, B-Y.
    Oum, C.
    Kim, S.
    Lim, Y.
    Park, G.
    Ock, C-Y.
    Shin, J. H.
    Yoo, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S226 - S226
  • [2] Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: A phase I study.
    Oh, Do-Youn
    Park, John J.
    Lee, Keun Wook
    Kim, Seung Tae
    Sriuranpong, Virote
    Rha, Sun Young
    Yoo, Changhoon
    Keam, Bhumsuk
    Sabanathan, Dhanusha
    Kim, Se Hyun
    Park, Joon Oh
    Parinyanitikul, Napa
    Kim, Min Hwan
    Kim, Kyu-Pyo
    Kim, Myungsuk
    Yoon, Jaebong
    Lee, Han Seung
    Ock, Chan-Young
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Safety, efficacy, and biomarker analysis of response to engineered tumor-infiltrating lymphocytes secreting anti-PD-1 antibody in recurrent glioblastoma: An open-label, two-arms, phase 1 study
    Yao, Yu
    Chen, Di
    Tang, Chao
    Ji, Chunxia
    Li, Zhong
    Qian, Qijun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a biomarker in locally advanced unresectable thymic epithelial neoplasm: A single-center, retrospective, longitudinal cohort study
    Kim, Dong Hyun
    Lim, Yoojoo
    Kim, Sukjun
    Ock, Chan-Young
    Youk, Jeonghwan
    Kim, Miso
    Kim, Tae Min
    Kim, Dong-Wan
    Kim, Hak Jae
    Koh, Jiwon
    Jung, Kyeong Cheon
    Na, Kwon Joong
    Kang, Chang Hyun
    Keam, Bhumsuk
    THORACIC CANCER, 2023, 14 (30) : 3001 - 3011
  • [5] Artificial intelligence (AI)-powered analysis of human epidermal growth factor receptor-2 (HER2) and tumor-infiltrating lymphocytes (TILs) in advanced biliary tract cancer (BTC)
    Kim, G.
    Kim, C.
    Kang, B.
    Shin, S.
    Lee, T.
    Song, S.
    Kim, S.
    Mostafavi, M.
    Song, H.
    Pereira, S.
    Chon, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S229 - S229
  • [6] A phase 2 study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (TIL, LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab in patients with locally advanced or metastatic NSCLC.
    Lee, Sylvia Mina
    Haigentz, Missak
    Villaruz, Liza Cosca
    Gorbatchevsky, Igor
    Suzuki, Sam
    Tanamly, Susie
    Samberg, Nancy Louise
    Fardis, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis
    Chen, Yueying
    Han, Hedong
    Cheng, Jing
    Cheng, Qinpei
    Zhu, Suhua
    Zhan, Ping
    Liu, Hongbing
    Song, Yong
    Lv, Tangfeng
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (08)
  • [8] Spatial Analysis of Tumor-Infiltrating Lymphocytes in mRCC Patients Treated with Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus plus GM-CSF) and cemiplimab (REGN2810; Anti-PD-1)
    Rha, S. Y.
    Bae, W. K.
    Kim, C.
    Ma, S.
    Oh, S. Y.
    Lee, H. J.
    Park, K.
    Mar, N.
    Pachynski, R.
    Mathias, M.
    Seebach, F.
    Folefac, E.
    Beom, S. H.
    Carranza, L.
    Merchan, J. R.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S79 - S80
  • [9] Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis (vol 73, 155, 2024)
    Chen, Yueying
    Han, Hedong
    Cheng, Jing
    Cheng, Qinpei
    Zhu, Suhua
    Zhan, Ping
    Liu, Hongbing
    Song, Yong
    Lv, Tangfeng
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (12)
  • [10] Biomarker analysis in the first-in-human phase 1a study for vantictumab (OMP-18R5; anti-Frizzled) demonstrates pharmacodynamic (PD) modulation of the Wnt pathway in patients with advanced solid tumors.
    Smith, David C.
    Rosen, Lee
    Wang, Min
    Zhang, Chun
    Xu, Lu
    Chughl, Rashmi
    Tolcher, Anthony
    Goldman, Jonathan
    Dupont, Jakob
    Brachmann, Raiiner K.
    Papadopoulos, Kyriakos
    Kapoun, Ann M.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
12